Cargando…

Untargeted Metabolomics and Steroid Signatures in Urine of Male Pattern Baldness Patients after Finasteride Treatment for a Year

Male pattern baldness (MPB) has been associated with dihydrotestosterone (DHT) expression. Finasteride treats MPB by inhibiting 5-alpha reductase and blocking DHT production. In this study, we aimed to identify metabolic differences in urinary metabolomics profiles between MPB patients after a one-y...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yu Ra, Im, Eunju, Kim, Haksoon, Lew, Bark Lynn, Sim, Woo-Young, Lee, Jeongae, Oh, Han Bin, Paeng, Ki Jung, Hong, Jongki, Chung, Bong Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241081/
https://www.ncbi.nlm.nih.gov/pubmed/32235609
http://dx.doi.org/10.3390/metabo10040131
_version_ 1783537021291069440
author Lee, Yu Ra
Im, Eunju
Kim, Haksoon
Lew, Bark Lynn
Sim, Woo-Young
Lee, Jeongae
Oh, Han Bin
Paeng, Ki Jung
Hong, Jongki
Chung, Bong Chul
author_facet Lee, Yu Ra
Im, Eunju
Kim, Haksoon
Lew, Bark Lynn
Sim, Woo-Young
Lee, Jeongae
Oh, Han Bin
Paeng, Ki Jung
Hong, Jongki
Chung, Bong Chul
author_sort Lee, Yu Ra
collection PubMed
description Male pattern baldness (MPB) has been associated with dihydrotestosterone (DHT) expression. Finasteride treats MPB by inhibiting 5-alpha reductase and blocking DHT production. In this study, we aimed to identify metabolic differences in urinary metabolomics profiles between MPB patients after a one-year treatment with finasteride and healthy controls. Untargeted and targeted metabolomics profiling was performed using liquid chromatography-mass spectrometry (LC-MS). We hypothesized that there would be changes in overall metabolite concentrations, especially steroids, in the urine of hair loss patients treated with finasteride and normal subjects. Untargeted analysis indicated differences in steroid hormone biosynthesis. Therefore, we conducted targeted profiling for steroid hormone biosynthesis to identify potential biomarkers, especially androgens and estrogens. Our study confirmed the differences in the concentration of urinary androgens and estrogens between healthy controls and MPB patients. Moreover, the effect of finasteride was confirmed by the DHT/T ratio in urine samples of MPB patients. Our metabolomics approach provided insight into the physiological alterations in MPB patients who have been treated with finasteride for a year and provided evidence for the association of finasteride and estrogen levels. Through a targeted approach, our results suggest that urinary estrogens must be studied in relation to MPB and post-finasteride syndrome.
format Online
Article
Text
id pubmed-7241081
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72410812020-06-02 Untargeted Metabolomics and Steroid Signatures in Urine of Male Pattern Baldness Patients after Finasteride Treatment for a Year Lee, Yu Ra Im, Eunju Kim, Haksoon Lew, Bark Lynn Sim, Woo-Young Lee, Jeongae Oh, Han Bin Paeng, Ki Jung Hong, Jongki Chung, Bong Chul Metabolites Article Male pattern baldness (MPB) has been associated with dihydrotestosterone (DHT) expression. Finasteride treats MPB by inhibiting 5-alpha reductase and blocking DHT production. In this study, we aimed to identify metabolic differences in urinary metabolomics profiles between MPB patients after a one-year treatment with finasteride and healthy controls. Untargeted and targeted metabolomics profiling was performed using liquid chromatography-mass spectrometry (LC-MS). We hypothesized that there would be changes in overall metabolite concentrations, especially steroids, in the urine of hair loss patients treated with finasteride and normal subjects. Untargeted analysis indicated differences in steroid hormone biosynthesis. Therefore, we conducted targeted profiling for steroid hormone biosynthesis to identify potential biomarkers, especially androgens and estrogens. Our study confirmed the differences in the concentration of urinary androgens and estrogens between healthy controls and MPB patients. Moreover, the effect of finasteride was confirmed by the DHT/T ratio in urine samples of MPB patients. Our metabolomics approach provided insight into the physiological alterations in MPB patients who have been treated with finasteride for a year and provided evidence for the association of finasteride and estrogen levels. Through a targeted approach, our results suggest that urinary estrogens must be studied in relation to MPB and post-finasteride syndrome. MDPI 2020-03-30 /pmc/articles/PMC7241081/ /pubmed/32235609 http://dx.doi.org/10.3390/metabo10040131 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Yu Ra
Im, Eunju
Kim, Haksoon
Lew, Bark Lynn
Sim, Woo-Young
Lee, Jeongae
Oh, Han Bin
Paeng, Ki Jung
Hong, Jongki
Chung, Bong Chul
Untargeted Metabolomics and Steroid Signatures in Urine of Male Pattern Baldness Patients after Finasteride Treatment for a Year
title Untargeted Metabolomics and Steroid Signatures in Urine of Male Pattern Baldness Patients after Finasteride Treatment for a Year
title_full Untargeted Metabolomics and Steroid Signatures in Urine of Male Pattern Baldness Patients after Finasteride Treatment for a Year
title_fullStr Untargeted Metabolomics and Steroid Signatures in Urine of Male Pattern Baldness Patients after Finasteride Treatment for a Year
title_full_unstemmed Untargeted Metabolomics and Steroid Signatures in Urine of Male Pattern Baldness Patients after Finasteride Treatment for a Year
title_short Untargeted Metabolomics and Steroid Signatures in Urine of Male Pattern Baldness Patients after Finasteride Treatment for a Year
title_sort untargeted metabolomics and steroid signatures in urine of male pattern baldness patients after finasteride treatment for a year
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241081/
https://www.ncbi.nlm.nih.gov/pubmed/32235609
http://dx.doi.org/10.3390/metabo10040131
work_keys_str_mv AT leeyura untargetedmetabolomicsandsteroidsignaturesinurineofmalepatternbaldnesspatientsafterfinasteridetreatmentforayear
AT imeunju untargetedmetabolomicsandsteroidsignaturesinurineofmalepatternbaldnesspatientsafterfinasteridetreatmentforayear
AT kimhaksoon untargetedmetabolomicsandsteroidsignaturesinurineofmalepatternbaldnesspatientsafterfinasteridetreatmentforayear
AT lewbarklynn untargetedmetabolomicsandsteroidsignaturesinurineofmalepatternbaldnesspatientsafterfinasteridetreatmentforayear
AT simwooyoung untargetedmetabolomicsandsteroidsignaturesinurineofmalepatternbaldnesspatientsafterfinasteridetreatmentforayear
AT leejeongae untargetedmetabolomicsandsteroidsignaturesinurineofmalepatternbaldnesspatientsafterfinasteridetreatmentforayear
AT ohhanbin untargetedmetabolomicsandsteroidsignaturesinurineofmalepatternbaldnesspatientsafterfinasteridetreatmentforayear
AT paengkijung untargetedmetabolomicsandsteroidsignaturesinurineofmalepatternbaldnesspatientsafterfinasteridetreatmentforayear
AT hongjongki untargetedmetabolomicsandsteroidsignaturesinurineofmalepatternbaldnesspatientsafterfinasteridetreatmentforayear
AT chungbongchul untargetedmetabolomicsandsteroidsignaturesinurineofmalepatternbaldnesspatientsafterfinasteridetreatmentforayear